Phase Ib/II Study of Axelopran in Combination with Nivolumab in Patients with Anti–PD-1–Refractory Unresectable or Metastatic Cutaneous Melanoma (SITC 2026) - Oct 2, 2026 - Abstract #569; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
Clinical • Combination therapy • Metastases • P1/2 data • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor
|
|
Nosakhare Ilerhunmwuwa; Anthony Cillo; John Kirkwood
|